Hansa Biopharma CEO to speak at BIO-Europe 2026

Hansa Biopharma CEO Renée Aguiar-Lucander will participate in the panel session "Immunology under the microscope: New frontiers" during the BIO-Europe 2026 conference. The event is scheduled for November 10 at 14:00 CET at the Koelnmesse in Cologne, Germany.

The session highlights ongoing industry focus on immunology, an area central to Hansa Biopharma’s therapeutic development. The appearance provides a platform for the firm to engage with stakeholders as it continues its operations in the specialty biopharmaceutical sector.

Investors and industry representatives looking to discuss the company’s current strategic direction may contact its investor relations department. The company remains headquartered in Lund, Sweden, and is publicly traded on Nasdaq Stockholm.